Aragen Life Sciences to Invest ₹1,500 Crore in Expansion Ahead of ₹800 Crore IPO

Source: ET Real Estate
Aragen Life Sciences has announced a ₹1,500 crore capital expenditure plan over the next three years to boost its drug development and manufacturing capacity. The company is preparing for its stock market debut, which includes a fresh issue of shares worth ₹800 crore.
- ▸Aragen Life Sciences plans to spend ₹1,500 crore on expansion over the next 36 months.
- ▸The company's upcoming IPO will include a fresh issue of ₹800 crore to fund growth.
- ▸Investment will focus on boosting capacity for drug manufacturing and biologics.
- ▸The firm is shifting focus from discovery services to integrated manufacturing for higher growth.
- ✓Aragen Life Sciences plans to spend ₹1,500 crore on expansion over the next 36 months.
- ✓The company's upcoming IPO will include a fresh issue of ₹800 crore to fund growth.
- ✓Investment will focus on boosting capacity for drug manufacturing and biologics.
- ✓The firm is shifting focus from discovery services to integrated manufacturing for higher growth.
Aragen Life Sciences, a leading contract research and manufacturing services provider, has unveiled an ambitious expansion roadmap involving a capital expenditure of ₹1,500 crore (₹15 billion) over the next three years. This strategic investment is designed to significantly scale up the company’s capabilities in drug development and manufacturing, catering to both small molecules and biologics.
IPO Details and Capital Raise
The expansion announcement comes as the company prepares for its Initial Public Offering (IPO). According to the Managing Director, the upcoming public issue will feature a fresh issue component of ₹800 crore. In addition to the fresh capital, the IPO will include an Offer for Sale (OFS) by existing shareholders, providing an exit or partial divestment route for current investors.
Strategic Focus on Manufacturing
While Aragen has historically derived a significant portion of its revenue from drug discovery services, the new investment signals a shift toward high-growth manufacturing segments. The ₹1,500 crore outlay will be utilized to:
- Enhance capacity for small molecule development.
- Build robust infrastructure for biologics manufacturing.
- Strengthen the company’s position in the global pharmaceutical supply chain.
Market Outlook
The company expects this capacity building to drive future revenue growth as global pharmaceutical firms increasingly outsource research and production to specialized Indian firms. By transitioning from a discovery-focused model to an integrated development and manufacturing organization, Aragen aims to capture a larger share of the life sciences value chain. For retail investors, the IPO represents an opportunity to enter the Contract Development and Manufacturing Organization (CDMO) space, which has seen heightened interest post-pandemic.
This report is for informational purposes only and does not constitute financial or investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
How much is Aragen Life Sciences raising through its IPO fresh issue?
The company plans to raise ₹800 crore through a fresh issue of shares as part of its stock market debut.
What is the purpose of the ₹1,500 crore investment?
The investment will be used over three years to expand drug development and manufacturing capacities, specifically for small molecules and biologics.
What does Aragen Life Sciences currently do?
Aragen is primarily a drug discovery and development service provider for the global life sciences industry.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate

Biocon Secures USFDA Approval for Breast Cancer Biosimilar Pebrilzo
Indian biopharmaceutical major Biocon Ltd has received approval from the US Food and Drug Administration (USFDA) for its biosimilar Pebrilzo, a treatment for HER2-positive breast cancer. This milestone expands Biocon's US oncology biosimilar portfolio to five products, with a global launch agreement with Genentech set for 2028.

Hair Loss in India: Are Vitamin D, Iron, and B12 Deficiencies the Hidden Cause?
Many Indians experiencing persistent hair loss might be overlooking a critical factor: nutritional deficiencies. Key vitamins and minerals like Vitamin D, iron, and B12 are essential for healthy hair, and their absence can manifest as tiredness, dry hair, or breakage, requiring professional diagnosis.

DRI Searches Cipla's Mumbai Office, Bhiwandi Depot Over Imported Drug Classification
The Directorate of Revenue Intelligence (DRI) recently conducted searches at pharmaceutical major Cipla's Mumbai office and Bhiwandi depot. The searches were related to the classification or exemption of an imported finished pharmaceutical product. Cipla has stated its full cooperation with authorities and anticipates no significant financial or operational impact.
Related Stories

Biocon Secures USFDA Approval for Breast Cancer Biosimilar Pebrilzo
Indian biopharmaceutical major Biocon Ltd has received approval from the US Food and Drug Administration (USFDA) for its biosimilar Pebrilzo, a treatment for HER2-positive breast cancer. This milestone expands Biocon's US oncology biosimilar portfolio to five products, with a global launch agreement with Genentech set for 2028.

Hair Loss in India: Are Vitamin D, Iron, and B12 Deficiencies the Hidden Cause?
Many Indians experiencing persistent hair loss might be overlooking a critical factor: nutritional deficiencies. Key vitamins and minerals like Vitamin D, iron, and B12 are essential for healthy hair, and their absence can manifest as tiredness, dry hair, or breakage, requiring professional diagnosis.

DRI Searches Cipla's Mumbai Office, Bhiwandi Depot Over Imported Drug Classification
The Directorate of Revenue Intelligence (DRI) recently conducted searches at pharmaceutical major Cipla's Mumbai office and Bhiwandi depot. The searches were related to the classification or exemption of an imported finished pharmaceutical product. Cipla has stated its full cooperation with authorities and anticipates no significant financial or operational impact.

Glenmark Launches Generic Kidney Cancer Drug in US, Targeting ₹4,490 Crore Market
Glenmark Pharmaceuticals Inc. U.S. has launched Axitinib Tablets, a generic version of Pfizer's Inlyta, in the United States for advanced kidney cancer treatment. This strategic move allows Glenmark to tap into a substantial market, with the original drug's annual sales previously reaching approximately ₹4,490 crore (USD 538.4 million) in the US.